ViCentra

Executive Summary

ViCentra is a Netherlands-based medical device and digital health company (founded 2015) that develops and commercializes the Kaleido insulin pump—an ultra-small, water-resistant, customizable patch pump designed to offer greater freedom and flexibility in diabetes management. The company integrates its hardware with advanced software algorithms, notably through a partnership with Diabeloop, to create hybrid closed-loop systems. With its patient-centric design and focus on miniaturization, ViCentra addresses key pain points in insulin delivery, such as discretion, wearability, and ease of use, positioning itself as a strong contender in the rapidly growing insulin pump market. The company's competitive edge lies in its ultra-compact form factor and partnerships that enable closed-loop automation. As diabetes prevalence rises and demand for less intrusive insulin delivery grows, ViCentra's Kaleido pump is well positioned to capture market share, particularly in Europe where it is already commercialized. The ongoing collaboration with Diabeloop to refine automated insulin delivery algorithms is a critical driver of future value. However, intense competition from established players like Insulet (Omnipod) and Medtronic, along with the need for further regulatory approvals and clinical validation, pose challenges. Overall, ViCentra represents an attractive opportunity in the diabetes tech space, with potential for significant growth if it achieves key regulatory and partnership milestones.

Upcoming Catalysts (preview)

• Q3 2026Regulatory approval for upgraded Kaleido pump in Europe75% success
• Q4 2026Announcement of new strategic partnership for US distribution50% success